PL 52
Alternative Names: PL-52Latest Information Update: 24 Oct 2023
At a glance
- Originator Jiangsu ProteLight Pharmaceutical and Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer; Triple negative breast cancer
Most Recent Events
- 20 Sep 2023 Early research in Colorectal cancer in China (Parenteral) before September 2023 (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)
- 20 Sep 2023 Early research in Colorectal cancer in China (PO) before September 2023 (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)
- 20 Sep 2023 Early research in Triple-negative-breast-cancer in China (Parenteral) before September 2023 (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)